E.g., 24/09/2020
E.g., 24/09/2020
PreviousNext

bioMérieux’s Annual General Meeting postponed  

09 April, 2020

Due to the unprecedented circumstances linked to the COVID-19 pandemic, the Board of Directors of bioMérieux, which met today, has decided to postpone the Annual General Meeting initially scheduled on May 19, 2020 to June 30, 2020. Depending on circumstances when...

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

24 March, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE...

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux  

11 March, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, is announcing the forthcoming launch of 3 different tests to address the COVID-19 epidemic and to meet the different needs of physicians and health authorities in the fight against this emerging infectious disease...

2019 Financial Results    

26 February, 2020

  • €2,675 million in sales for full-year 2019, representing a reported increase of 10.5% and organic growth of 7.2% 
  • Strong sales momentum in the fourth quarter, with organic growth of 8.3% driven by sales of molecular...

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

13 January, 2020

 

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for...

bioMérieux and the Fleming Fund: working together to strengthen diagnostic capacity and tackle antimicrobial resistance in low- and middle-income countries

18 December, 2019

London (UK), Marcy l’Étoile (France) – December 18, 2019 – bioMérieux, a world leader in in vitro diagnostics which develops and manufactures testing solutions (systems, reagents, software, services) mainly used for diagnosing infectious diseases, has been selected...

Third-Quarter 2019 Business Review

22 October, 2019

  • Organic growth of 6.8% at constant exchange rates and scope of consolidation over the first nine months of the year:
    • €1,928 million in sales 
    • Up 10.3% as...

First-Half 2019 Results

04 September, 2019

bioMérieux – First-Half 2019 Results

 

  • Organic sales growth of 5.5% for first-half 2019:
    • €1,275 million in sales
    • Up 9.1% as reported
  • As expected...

bioMérieux increases its holding in Hybiome from 54% to 67%

06 June, 2019

 
bioMérieux, a world leader in the field of in vitro diagnostics, today announced an increase of its shareholding in Suzhou Hybiome Biomedical Engineering Co. Ltd. This announcement follows the earlier announcement of the acquisition of a majority stake in this...

NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in the ERAS “Guidelines for Perioperative Care in Cardiac Surgery”

13 May, 2019

The NEPHROCHECK® Test biomarkers (TIMP-2 and IGFBP7) that indicate kidney stress in advance of acute kidney injury (AKI) have been included in the “Guidelines for Perioperative Care in Cardiac Surgery” which were published by the ERAS® (Enhanced Recovery After...

PreviousNext